KY-226
Product Specifications
UNSPSC Description
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury[1][2].
Target Antigen
Phosphatase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ky-226.html
Purity
98.28
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(NS(=O)(CCCCCC)=O)C1=CC=C(CSCC2=CC=C(C3=CC=CC=C3)C=C2)C=C1
Molecular Weight
481.67
References & Citations
[1]Ito Y, et al. Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice. J Pharmacol Sci. 2018 May;137(1):38-46.|[2]Sun M, et al. KY-226 Protects Blood-brain Barrier Function Through the Akt/FoxO1 Signaling Pathway in Brain Ischemia. Neuroscience. 2019 Feb 10;399:89-102.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-120327/KY-226-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-120327/KY-226-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1621673-53-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6195002-01 0.1 mL
CLK3 (CDC-like Kinase 3, FLJ22858, PHCLK3, PHCLK3/152) (MaxLight 405)
Ask
View Details 
MBS6195002-02 5x 0.1 mL
CLK3 (CDC-like Kinase 3, FLJ22858, PHCLK3, PHCLK3/152) (MaxLight 405)
Ask
View Details